{"id":526574,"date":"2021-08-11T08:08:16","date_gmt":"2021-08-11T12:08:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\/"},"modified":"2021-08-11T08:08:16","modified_gmt":"2021-08-11T12:08:16","slug":"outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\/","title":{"rendered":"Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology\u00a0Virtual Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong>Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, to participate in <\/strong><br \/>\n          <strong><br \/>\n            <em>The Greatest Unmet Needs Facing Ophthalmology Today <\/em><br \/>\n          <\/strong><br \/>\n          <strong>panel on Tuesday, August 17<\/strong><br \/>\n          <sup><br \/>\n            <strong>th<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> at 9:00 AM ET<\/strong><br \/>\n          \n        <\/li>\n<\/ul>\n<p align=\"justify\">ISELIN, N.J., Aug.  11, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MDnD9q5igvXAEOpqMhwco8ESHSe12MvxDgCKt5VWKAhrMveQtd5vRfq5fvlBhh--j17naSa3Y68ZCZZbBiaQalGO82zeenQcvhN0Oe-1qHo=\" rel=\"nofollow noopener\" target=\"_blank\">Outlook Therapeutics, Inc.<\/a> (Nasdaq: OTLK), a biopharmaceutical company\u202fworking to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab\u202ffor use in retinal\u202findications, today announced that C. Russell Trenary III, President and Chief Executive Officer of Outlook Therapeutics, will participate in the H.C. Wainwright Ophthalmology Virtual Conference being held Tuesday, August 17, 2021 from 9:00 \u2013 10:00 a.m. ET .<\/p>\n<p align=\"justify\">As part of the event, Mr. Trenary will participate in the panel, hosted by Matthew Caufield, Equity Research Analyst at H.C. Wainwright, <em>The Greatest Unmet Needs Facing Ophthalmology Today<\/em>. To register for the event, please visit the conference website <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M_riJXbzgz7M1ggC646MEku7-xyLhKLnKn-ACpgWAfyAEoGAHND3kbTJ-jZY7mpea41t4qmOV65QXGGILQV_I_mmaImk4suN_yYe2MyAzZfIa1UEXlSjdjQtF6TJDQ6Q\" rel=\"nofollow noopener\" target=\"_blank\"><strong>here<\/strong><\/a>.<\/p>\n<p align=\"justify\">Outlook Therapeutics recently announced positive clinical and highly statistically significant top-line results from its pivotal Phase 3 NORSE TWO safety and efficacy trial evaluating ONS-5010 \/ LYTENAVA\u2122 (bevacizumab) for treatment of neovascular age-related macular degeneration (wet AMD). Because no currently approved ophthalmic formulations of bevacizumab are available, clinicians wishing to treat retinal patients with bevacizumab have had to use unapproved repackaged IV bevacizumab provided by compounding pharmacists, products that have known risks of contamination and inconsistent potency and availability.<\/p>\n<p align=\"justify\">\n        <strong>About Outlook Therapeutics, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010 \/ LYTENAVA\u2122 (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 ophthalmic bevacizumab with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-G3d0enFrWg-kY-CGNHbhwzLiJYUbOKxPdEaTy-4Ew10WP0Jy8K-kSsilsCtNiksOEg8q7HbFI37cUAzmLRK6JCLzmqXbz7v1zShsdwA91QrCsiPGGyBnEshaj_itrlz\" rel=\"nofollow noopener\" target=\"_blank\">www.outlooktherapeutics.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements. All statements other than statements of historical facts are \u201cforward-looking statements,\u201d including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cproject,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201cintend\u201d or \u201ccontinue,\u201d the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, statements about ONS-5010\u2019s potential as the first FDA-approved ophthalmic formulation of bevacizumab-vikg, including benefits therefrom to patients, payors and physicians. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing pharmaceutical product candidates, risks of conducting clinical trials and risks in obtaining necessary regulatory approvals, as well as those risks detailed in Outlook Therapeutics\u2019 filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the fiscal year ended September 30, 2020, as amended, and subsequent Quarterly Reports on Form 10-Q, which include the uncertainty of future impacts related to the ongoing COVID-19 pandemic. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.<\/p>\n<p>\n        <strong>CONTACTS:<\/strong>\n      <\/p>\n<p>\n        <strong>Media Inquiries:<br \/><\/strong>Harriet Ullman<br \/>Vice President<br \/>LaVoie Health Science<br \/>T: 617-669-3082<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tOAQrmeXOeo6mLgZrNj1eG7RugVT47LViwPnYihJPhaDO93PMC8cKxYgf0vtdOFCo-uf1Ko23iebUYL83_6mKUbS1TjEwVWgwNYlmV7j3uv6jvP8pk8sy2spGhJTmteI\" rel=\"nofollow noopener\" target=\"_blank\">hullman@lavoiehealthscience.com<\/a><\/p>\n<p>\n        <strong>Investor Inquiries:<br \/><\/strong>Jenene Thomas<br \/>Chief Executive Officer<br \/>JTC Team, LLC<br \/>T: 833.475.8247<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GHCae_EcTAY77_j3SSQyZOAtbOmaVRvipENosIbJQ_Odrp2PyNsrEciCmVTAB_wTjSqV4RzfDCeucfcLJOeKYg==\" rel=\"nofollow noopener\" target=\"_blank\">OTLK@jtcir.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNjgwOCM0MzUyMTg1IzIwMjg4MjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MTFlOTY1YTAtOTNhMS00MTIwLTgzMzItYTFkYzk5ZGQ4N2Y0LTEwNDAzOTM=\/tiny\/Outlook-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, to participate in The Greatest Unmet Needs Facing Ophthalmology Today panel on Tuesday, August 17 th at 9:00 AM ET ISELIN, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) &#8212; Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company\u202fworking to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab\u202ffor use in retinal\u202findications, today announced that C. Russell Trenary III, President and Chief Executive Officer of Outlook Therapeutics, will participate in the H.C. Wainwright Ophthalmology Virtual Conference being held Tuesday, August 17, 2021 from 9:00 \u2013 10:00 a.m. ET . As part of the event, Mr. Trenary will participate in the panel, hosted by Matthew Caufield, Equity Research Analyst at H.C. Wainwright, The &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology\u00a0Virtual Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-526574","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology\u00a0Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology\u00a0Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, to participate in The Greatest Unmet Needs Facing Ophthalmology Today panel on Tuesday, August 17 th at 9:00 AM ET ISELIN, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) &#8212; Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company\u202fworking to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab\u202ffor use in retinal\u202findications, today announced that C. Russell Trenary III, President and Chief Executive Officer of Outlook Therapeutics, will participate in the H.C. Wainwright Ophthalmology Virtual Conference being held Tuesday, August 17, 2021 from 9:00 \u2013 10:00 a.m. ET . As part of the event, Mr. Trenary will participate in the panel, hosted by Matthew Caufield, Equity Research Analyst at H.C. Wainwright, The &hellip; Continue reading &quot;Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology\u00a0Virtual Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-11T12:08:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNjgwOCM0MzUyMTg1IzIwMjg4MjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology\u00a0Virtual Conference\",\"datePublished\":\"2021-08-11T12:08:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\\\/\"},\"wordCount\":677,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNjgwOCM0MzUyMTg1IzIwMjg4MjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\\\/\",\"name\":\"Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology\u00a0Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNjgwOCM0MzUyMTg1IzIwMjg4MjI=\",\"datePublished\":\"2021-08-11T12:08:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNjgwOCM0MzUyMTg1IzIwMjg4MjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNjgwOCM0MzUyMTg1IzIwMjg4MjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology\u00a0Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology\u00a0Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology\u00a0Virtual Conference - Market Newsdesk","og_description":"Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, to participate in The Greatest Unmet Needs Facing Ophthalmology Today panel on Tuesday, August 17 th at 9:00 AM ET ISELIN, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) &#8212; Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company\u202fworking to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab\u202ffor use in retinal\u202findications, today announced that C. Russell Trenary III, President and Chief Executive Officer of Outlook Therapeutics, will participate in the H.C. Wainwright Ophthalmology Virtual Conference being held Tuesday, August 17, 2021 from 9:00 \u2013 10:00 a.m. ET . As part of the event, Mr. Trenary will participate in the panel, hosted by Matthew Caufield, Equity Research Analyst at H.C. Wainwright, The &hellip; Continue reading \"Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology\u00a0Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-11T12:08:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNjgwOCM0MzUyMTg1IzIwMjg4MjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology\u00a0Virtual Conference","datePublished":"2021-08-11T12:08:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\/"},"wordCount":677,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNjgwOCM0MzUyMTg1IzIwMjg4MjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\/","name":"Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology\u00a0Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNjgwOCM0MzUyMTg1IzIwMjg4MjI=","datePublished":"2021-08-11T12:08:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNjgwOCM0MzUyMTg1IzIwMjg4MjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNjgwOCM0MzUyMTg1IzIwMjg4MjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-participate-at-the-h-c-wainwright-ophthalmology-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology\u00a0Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/526574","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=526574"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/526574\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=526574"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=526574"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=526574"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}